Airsonett

Recent independent studies confirm that the TLA technology in the Airsonett Air4 device achieves a mean reduction of airborne particles between 99.95% to 99.99% in the breathing zone. Clinical research demonstrates significant reductions in exacerbations and improved control of allergic diseases with no pharmacological side effects. The treatment improves quality of life and sleep for patients with allergic diseases and has been shown to be cost-effective compared to pharmacological add-ons. The product holds CE mark as a class I medical device under MDR2017/745 and FDA clearance as a class II device. Over 800 patients are currently treated within the Swedish healthcare system.